Cited by 241Liver Diseases and ImmunityTelomeres, Telomerase, and SenescenceLiver physiology and pathology

Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis

Open access
Tabibian, James H., O'Hara, Steven P., Splinter, Patrick L., Trussoni, Christy E., LaRusso, Nicholas F.·2014·Hepatology

Abstract

Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis. Here we tested the hypothesis that cholangiocyte senescence is a pathophysiologically important phenotype in PSC. We assessed markers of cellular senescence and senescence-associated secretory phenotype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluorescent in situ hybridization (FISH) and immunofluorescence microscopy (IFM). We tested whether endogenous and exogenous biliary constituents affect senescence and SASP in cultured human cholangiocytes. We determined in coculture whether senescent cholangiocytes induce senescence in bystander cholangiocytes. Finally, we explored signaling mechanisms involved in cholangiocyte senescence and SASP. In vivo , PSC cholangiocytes expressed significantly more senescence-associated p16 INK4a and γH2A.x compared to the other three conditions; expression of profibroinflammatory SASP components (i.e., IL-6, IL-8, CCL2, PAI-1) was also highest in PSC cholangiocytes. In vitro , several biologically relevant endogenous (e.g., cholestane 3,5,6 oxysterol) and exogenous (e.g., lipopolysaccharide) molecules normally present in bile induced cholangiocyte senescence and SASP. Furthermore, experimentally induced senescent human cholangiocytes caused senescence in bystander cholangiocytes. N-Ras, a known inducer of senescence, was increased in PSC cholangiocytes and in experimentally induced senescent cultured cholangiocytes; inhibition of Ras abrogated experimentally induced senescence and SASP. Conclusion : Cholangiocyte senescence induced by biliary constituents by way of N-Ras activation is an important pathogenic mechanism in PSC. Pharmacologic inhibition of N-Ras with a resultant reduction in cholangiocyte senescence and SASP is a new therapeutic approach for PSC. (Hepatology 2014;59:2263–2275)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26993

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cholangiocytes can undergo lipoapoptosis and senescence when exposed to increased saturated fatty acids, releasing DAMPs, SASP factors such as CCL2, and SPP1 that activate HSCs and generate fibrosis.

    “Like hepatocytes, cholangiocytes can undergo lipoapoptosis and senescence in the presence of increased saturated fatty acids, which may provoke release of damage-associated molecular patterns, senescence-associated secretory patterns (such as chemokine ligand 2 (CCL2)), and SPP1, which activate HSCs to generate fibrosis (37-40).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 49 · Cited by 241

Authors
Tabibian, J. H., O'Hara, S. P., Splinter, P. L., Trussoni, C. E., & LaRusso, N. F.
Affiliations
Mayo Clinic (US)
Corresponding author
LaRusso, Nicholas F.
Venue
Hepatology
Published
2014-06
Volume
59
Issue
6
Pages
2263-2275
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2113586342
Cited by
241
References
49
Citations by year
2026: 9 · 2025: 10 · 2024: 20 · 2023: 20 · 2022: 17 · 2021: 36 · 2020: 18 · 2019: 22 · 2018: 23 · 2017: 27 · 2016: 14 · 2015: 17 · 2014: 8
FWCI
12.31
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (R01AI089713, AI089713)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK57993, P30DK084567, R01DK057993)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
primary sclerosing cholangitis, senescence-associated secretory phenotype, NRAS, p16INK4a, γH2AX, bile composition, lipopolysaccharide, primary biliary cirrhosis
MeSH terms
Adult, Cells, Cultured, Enzyme Activation, Humans, Middle Aged, Phenotype, Genes, ras, Bodily Secretions, Cholangitis, Sclerosing, Case-Control Studies, Cellular Senescence, ras Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review